Cognitive Behavioral Therapy for Body Image Distress in Head and Neck Cancer Survivors
(BRIGHT Trial)
Trial Summary
What is the purpose of this trial?
In this multi-center randomized clinical trial, head and neck cancer (HNC) survivors with clinically significant body image distress (BID) (N=180) will be randomized to BRIGHT (a brief video tele-cognitive behavioral therapy intervention) or Attention Control (AC, a manualized tele-supportive care intervention that controls for professional attention, dose, delivery method, and common factors). HNC survivors will complete IMAGE-HN (a validated patient-reported outcome measure \[PROM\] of HNC-related body image distress \[BID\]; primary endpoint), measures of psychological and social well-being and quality of life (QOL), and measures of theory-derived mechanisms of change underlying BRIGHT (mediators).
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, if you have started or adjusted psychotropic medication in the last 3 months, you may not be eligible to participate.
What data supports the effectiveness of the treatment for body image distress in head and neck cancer survivors?
Is Cognitive Behavioral Therapy safe for head and neck cancer survivors with body image distress?
How is the BRIGHT treatment different from other treatments for body image distress in head and neck cancer survivors?
Eligibility Criteria
This trial is for adults over 18 who've had curative surgery for head and neck cancer within the last year, are now cancer-free, and experience significant body image distress. They must not be planning major surgeries during the study and should not have severe psychiatric issues or ongoing cognitive behavioral therapy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized to either BRIGHT or Attention Control interventions delivered via video tele-cognitive behavioral therapy or tele-supportive care
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 2, 3, 6, and 9 months post-randomization
Treatment Details
Interventions
- Attention Control
- BRIGHT
Find a Clinic Near You
Who Is Running the Clinical Trial?
Medical University of South Carolina
Lead Sponsor
National Cancer Institute (NCI)
Collaborator